ArticleBlood2015
How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses.
Article in Blood, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma.JAMA network open · 2021Trial
- Targeted and molecular therapies in Ewing sarcoma: a comprehensive review of preclinical and clinical advances.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Valuing treatment in oncology: embracing a broader notion of value.Journal of managed care & specialty pharmacy · 2022Article
- First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.Cancers · 2021Article
- Navigating Ethical Practices in the Era of High Cost Hematology.Current hematologic malignancy reports · 2020Review
- Cancer drug development: The missing links.Experimental biology and medicine (Maywood, N.J.) · 2019Review
- The economic impact of the transition from branded to generic oncology drugs.Current oncology (Toronto, Ont.) · 2019Article
- The high price of anticancer drugs: origins, implications, barriers, solutions.Nature reviews. Clinical oncology · 2017Review
- Treatment of newly diagnosed myeloma: Bortezomib-based triplet.Seminars in oncology · 2016Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.